Vanguard Group Inc. Has $80.56 Million Stock Holdings in Trevi Therapeutics, Inc. $TRVI

Vanguard Group Inc. grew its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 10.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,434,655 shares of the company’s stock after purchasing an additional 607,669 shares during the quarter. Vanguard Group Inc. owned approximately 5.02% of Trevi Therapeutics worth $80,562,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. NBC Securities Inc. boosted its stake in shares of Trevi Therapeutics by 750.0% during the fourth quarter. NBC Securities Inc. now owns 17,000 shares of the company’s stock valued at $213,000 after purchasing an additional 15,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Trevi Therapeutics by 85.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,681 shares of the company’s stock valued at $584,000 after purchasing an additional 21,503 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Trevi Therapeutics by 93.0% during the fourth quarter. SG Americas Securities LLC now owns 124,562 shares of the company’s stock valued at $1,560,000 after purchasing an additional 60,017 shares in the last quarter. Finally, Diversified Trust Co. boosted its stake in shares of Trevi Therapeutics by 14.6% during the fourth quarter. Diversified Trust Co. now owns 20,984 shares of the company’s stock valued at $263,000 after purchasing an additional 2,675 shares in the last quarter. 95.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TRVI. D. Boral Capital reissued a “buy” rating and set a $19.00 price target on shares of Trevi Therapeutics in a research note on Friday, April 17th. Stifel Nicolaus set a $30.00 price target on Trevi Therapeutics in a research note on Friday, May 8th. Needham & Company LLC cut their price objective on Trevi Therapeutics from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Wall Street Zen lowered Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, JonesTrading cut their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $22.90.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $15.27 on Thursday. The stock’s 50 day moving average is $12.93 and its 200 day moving average is $12.07. The firm has a market cap of $2.17 billion, a P/E ratio of -47.72 and a beta of 1.07. Trevi Therapeutics, Inc. has a one year low of $5.38 and a one year high of $16.12.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.45 earnings per share for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.